Coffin-Siris syndrome: genes and variants
Explore variant evidence for Coffin-Siris syndrome across 6 analyzed proteins (ARID1B, SMARCE1, ARID2, SMARCB1, ARID1A and 1 more). Linked ClinVar records include 18 pathogenic or likely pathogenic variants, 129 variants of uncertain significance and 54 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Coffin-Siris syndrome
ARID1B: AT-rich interactive domain-containing protein 1B
It helps SWI/SNF chromatin-remodeling complexes regulate access to developmental gene programs, especially in the nervous system. Haploinsufficiency is a major cause of Coffin-Siris syndrome and related neurodevelopmental disorders.
10 ClinVar pathogenic / likely pathogenic and 113 uncertain variants in ARID1B have source records linked to Coffin-Siris syndrome. Association strength is not clinical gene validity.
SMARCE1: SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1
It helps SWI/SNF chromatin-remodeling complexes interact with nucleosomes and transcriptional regulators. Germline loss-of-function variants predispose to clear-cell meningiomas, often presenting at young ages or at multiple sites.
3 ClinVar pathogenic / likely pathogenic and 15 uncertain variants in SMARCE1 have source records linked to Coffin-Siris syndrome. Association strength is not clinical gene validity.
ARID2: AT-rich interactive domain-containing protein 2
It contributes DNA targeting and regulatory specificity to PBAF chromatin-remodeling complexes. Somatic loss-of-function alterations occur in melanoma, liver cancer, and other tumors, while germline variants can cause a Coffin-Siris-spectrum neurodevelopmental disorder.
2 ClinVar pathogenic / likely pathogenic and 43 uncertain variants in ARID2 have source records linked to Coffin-Siris syndrome. Association strength is not clinical gene validity.
SMARCB1: SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1
Within SWI/SNF complexes, it constrains oncogenic transcription and supports normal chromatin regulation. Biallelic tumor-cell inactivation is characteristic of malignant rhabdoid tumors, while germline variants predispose to rhabdoid tumors or schwannomatosis.
2 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in SMARCB1 have source records linked to Coffin-Siris syndrome. Association strength is not clinical gene validity.
ARID1A: AT-rich interactive domain-containing protein 1A
It helps BAF chromatin-remodeling complexes open or reposition nucleosomes at regulatory regions and thereby control lineage-specific transcription. Somatic loss is frequent in several cancers, while germline haploinsufficiency can cause Coffin-Siris syndrome.
1 ClinVar pathogenic / likely pathogenic and 9 uncertain variants in ARID1A have source records linked to Coffin-Siris syndrome. Association strength is not clinical gene validity.
SMARCA4: SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4
Its ATPase activity drives nucleosome remodeling in BAF-family complexes and thereby controls access to regulatory DNA. Germline pathogenic variants cause Coffin-Siris syndrome or rhabdoid-tumor predisposition, while somatic loss defines several aggressive cancers.
0 ClinVar pathogenic / likely pathogenic and 2 uncertain variants in SMARCA4 have source records linked to Coffin-Siris syndrome. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): SMARCA2.
ClinVar pathogenic and likely pathogenic variants linked to Coffin-Siris syndrome
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| SMARCE1 R105Q | 105 | HMG box | Pathogenic / likely pathogenic (★★★★) |
| SMARCB1 R374Q | 374 | Pathogenic / likely pathogenic (★★) | |
| SMARCE1 K92N | 92 | HMG box | Pathogenic / likely pathogenic (★★) |
| ARID1B M2035T | 2035 | Pathogenic / likely pathogenic (★★) | |
| SMARCB1 R37H | 37 | DNA-binding | Pathogenic / likely pathogenic (★★) |
| ARID1B G30S | 30 | Pathogenic / likely pathogenic (★★) | |
| ARID1B G761R | 761 | Pathogenic / likely pathogenic (★) | |
| ARID1B G1182A | 1182 | ARID | Pathogenic / likely pathogenic (★) |
| ARID1B V2022G | 2022 | Pathogenic / likely pathogenic (★) | |
| ARID1B L2153P | 2153 | Pathogenic / likely pathogenic (★) | |
| ARID2 S297F | 297 | Pathogenic / likely pathogenic (★) | |
| ARID2 I943S | 943 | Pathogenic / likely pathogenic (★) | |
| ARID1B G89D | 89 | Pathogenic / likely pathogenic (★) | |
| ARID1B V2075G | 2075 | Pathogenic / likely pathogenic (★) | |
| ARID1B D364N | 364 | Pathogenic / likely pathogenic (★) | |
| ARID1A K1021E | 1021 | ARID | Pathogenic / likely pathogenic |
| SMARCE1 Y73S | 73 | HMG box | Pathogenic / likely pathogenic |
| ARID1B K1115N | 1115 | Pathogenic / likely pathogenic |
Which prediction tools work for Coffin-Siris syndrome
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- MutPred: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 92 out of 100
- MetaSVM: 82 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- PolyPhen-2: 81 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 80 out of 100
- CATVariant: 80 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 77 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SIFT: 74 out of 100
Same protein, different disease
- Familial meningioma also has ClinVar records linked to SMARCE1 variants; they fall mostly in different places as the Coffin-Siris syndrome variants (4 pathogenic / likely pathogenic).
Diseases related to Coffin-Siris syndrome
- Rhabdoid tumor predisposition syndrome, also linked to SMARCA4 and SMARCB1
- Lung adenocarcinoma, also linked to ARID1A and SMARCA4
- Hepatocellular carcinoma, also linked to ARID1A and ARID2
- Colorectal cancer, also linked to ARID1A
- Urinary bladder cancer, also linked to ARID1A
- Non-small cell lung carcinoma, also linked to SMARCA4
- NK-cell enteropathy, also linked to SMARCB1
- Familial meningioma, also linked to SMARCE1
- Esophageal cancer, also linked to ARID1A
- Medulloblastoma, also linked to SMARCA4
- Marfanoid habitus and intellectual disability, also linked to ARID1B
- Melanoma, also linked to ARID2
Frequently asked questions
Which genes have records linked to Coffin-Siris syndrome?
This view contains 6 analyzed proteins: ARID1B, SMARCE1, ARID2, SMARCB1, ARID1A and 1 more. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 18 pathogenic or likely pathogenic variants, 129 variants of uncertain significance and 54 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 307 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center